Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Prostate Cancer: Molecular Imaging and Radionuclide Therapy
share announcement

Prostate Cancer: Molecular Imaging and Radionuclide Therapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 6310

Special Issue Editor

Dr. Sara Harsini

E-Mail Website
Guest Editor
BC Cancer Research Institute, Vancouver, BC, Canada
Interests: medical imaging; molecular imaging; PET/CT; theranostics; cancer imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am thrilled to announce the upcoming release of a Special Issue in Biomedicines, entitled "Prostate Cancer: Molecular Imaging and Radionuclide Therapy." This collection of articles will feature contributions from leading experts in the field of positron emission tomography/computed tomography (PET/CT) and radionuclide therapies for prostate cancer. The rapidly evolving field of theranostics, which combines diagnostic and therapeutic radiopharmaceutical agents, is revolutionizing prostate cancer imaging and paving the way for improved treatment strategies. This Special Issue aims to highlight recent advancements in molecular imaging and radionuclide therapy that have already impacted the management of prostate cancer and those that have the potential to shape the diagnostic and treatment paths of the disease in the near future.

Dr. Sara Harsini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • theranostics
  • positron emission tomography
  • PET
  • radionuclide therapy
  • prostate-specific membrane antigen

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1170 KiB  
Review
Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?
by Jules Zhang-Yin
Biomedicines 2024, 12(7), 1512; https://doi.org/10.3390/biomedicines12071512 - 8 Jul 2024
Cited by 1 | Viewed by 1867
Abstract
Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC). Personalized dosimetry, facilitated by post-therapeutic imaging, offers the potential to enhance treatment efficacy by customizing radiation doses to individual patient [...] Read more.
Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC). Personalized dosimetry, facilitated by post-therapeutic imaging, offers the potential to enhance treatment efficacy by customizing radiation doses to individual patient needs, thereby maximizing therapeutic benefits while minimizing toxicity to healthy tissues. However, implementing personalized dosimetry is resource-intensive, requiring multiple single-photon emission-computed tomography (SPECT)/CT scans and posing significant logistical challenges for both healthcare facilities and patients. Despite these challenges, personalized dosimetry can lead to optimized radiation delivery, improved safety, and better management of complex cases. Nevertheless, the financial and resource burdens complicate its adoption in routine clinical practice. While the European Association of Nuclear Medicine (EANM) supports personalized dosimetry, standardization is lacking due to these practical constraints. Further research and streamlined methodologies are essential to balance the benefits and feasibility of personalized dosimetry, potentially improving treatment outcomes for mCRPC patients. Full article
(This article belongs to the Special Issue Prostate Cancer: Molecular Imaging and Radionuclide Therapy)
►▼ Show Figures

Figure 1

25 pages, 1887 KiB  
Review
Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire
by Nima Nabavi, Seied Rabi Mahdavi, Mohammad Afshar Ardalan, Mohsen Chamanara, Reza Mosaed, Aline Lara, Diogo Bastos, Sara Harsini, Emran Askari, Pedro Isaacsson Velho and Hamed Bagheri
Biomedicines 2023, 11(7), 2084; https://doi.org/10.3390/biomedicines11072084 - 24 Jul 2023
Cited by 4 | Viewed by 3275
Abstract
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and adapt to the castrate state through autoregulation of the androgen receptor. Additionally, the [...] Read more.
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and adapt to the castrate state through autoregulation of the androgen receptor. Additionally, the upfront use of novel hormonal agents such as enzalutamide and abiraterone acetate may result in long-term toxicities and may trigger the selection of AR-independent cells through “Darwinian” treatment-induced pressure. Therefore, it is crucial to develop new strategies to overcome these challenges. Bipolar androgen therapy (BAT) is one such approach that has been devised based on studies demonstrating the paradoxical inhibitory effects of supraphysiologic testosterone on prostate cancer growth, achieved through a variety of mechanisms acting in concert. BAT involves rapidly alternating testosterone levels between supraphysiological and near-castrate levels over a period of a month, achieved through monthly intramuscular injections of testosterone plus concurrent ADT. BAT is effective and well-tolerated, improving quality of life and potentially re-sensitizing patients to previous hormonal therapies after progression. By exploring the mechanisms and clinical evidence for BAT, this review seeks to shed light on its potential as a promising new approach to prostate cancer treatment. Full article
(This article belongs to the Special Issue Prostate Cancer: Molecular Imaging and Radionuclide Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop